Compare TIL & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIL | NSPR |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 67.4M |
| IPO Year | N/A | N/A |
| Metric | TIL | NSPR |
|---|---|---|
| Price | $8.73 | $1.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $125.00 | $4.00 |
| AVG Volume (30 Days) | ★ 69.8K | 26.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $22.91 |
| Revenue Next Year | N/A | $72.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.67 | $1.51 |
| 52 Week High | $42.79 | $3.80 |
| Indicator | TIL | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 51.96 |
| Support Level | $7.51 | $1.60 |
| Resistance Level | $7.87 | $1.83 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 91.03 | 58.22 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.